Elsevier

EXPLORE

Volume 10, Issue 1, January–February 2014, Pages 53-54
EXPLORE

Research Letter
Low-Level Electric Current and Cancer–A Promising, but Languishing Non-Toxic Cancer Therapy

https://doi.org/10.1016/j.explore.2013.10.004Get rights and content

Section snippets

Introduction—Scientific Basis of GEIPE Cancer Therapy

At biochemical level, all cancers are alike. In order for a cell to divide in any organ, its DNA strand must be replicated. Of the various enzymes involved in the process of DNA synthesis, none is more critical than ribonucleotide reductase (RnR), which provides the building blocks—four bases—of DNA, by reducing the corresponding, abundantly available, bases of RNA. The activity of this RnR enzyme is most closely linked to malignant transformation and tumor cell proliferation.1

This

Compelling Experimental Evidence

Long before the mechanism was proposed on how low-level electric current might stop cancerous growth, about 10 cancer electrotherapy studies had been reported in the scientific literature. The results of all these studies are consistent with the mechanism involving destruction of the free-radical-containing active site of the enzyme RnR.

The first such study was published in 1959 in the journal Science.5 It reported “complete disappearance of tumor” in 60% of test animals after 21 days when they

Effectiveness in Human Patients

Over the years, the author has built various GEIPE devices, constantly improving them and has treated a few patients whose cancer no longer responded to conventional treatments or who were averse to conventional toxic therapies.

One Nigerian physician, after consulting with the author, successfully treated a large malignant squamous cell carcinoma of the sinus cavity in a woman with a GEIPE device (Figure 1).

The treatment was given eight hours daily and lasted for eight weeks. Further details of

Unique Difficulties in Establishing GEIPE Therapy

More than 15 years ago, the MD Anderson Cancer Center, Houston and the National Cancer Institute of USA acknowledged the validity of this approach to treat cancer in correspondence with the author (personal communication). However, no effort has been made by any institution to explore and standardize this treatment, as the process would present unique challenges.

To establish any treatment and get approval from Food and Drug Administration (FDA), human clinical trials in three phases must be

References (7)

There are more references available in the full text version of this article.
View full text